Search results
Showing 151 to 200 of 8201 results
Gynaecological conditions: rates of hysterectomy (heavy menstrual bleeding) (IND58)
This indicator covers rates of hysterectomy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG77
Pregnancy and neonates: mental health at booking appointment (IND63)
This indicator covers proportion of pregnant women who were asked about their mental health at their first booking appointment. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG82
This indicator covers mortality rates directly associated with VTE. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG80
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.
Agenda and papers of the NICE public board meeting on 20 March 2024
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.
Charging procedure: technology appraisal and highly specialised technologies evaluations
Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Show all sections
Sections for NG51
- Overview
- Could this be sepsis?
- Face to face assessment
- Under 16s: evaluating risk and managing suspected sepsis
- Pregnant or recently pregnant people: evaluating risk and managing suspected sepsis
- Over 16s (not pregnant or recently pregnant): evaluating risk and managing suspected sepsis
- Antibiotic therapy, intravenous fluid and oxygen
- Finding and controlling the source of infection
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management....
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Resources to help organisations who want to help develop NICE guidance
Take part in the production of medical technologies guidance.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
We're bringing our guidance together by topic, so that it's all in one place, clearer to understand and easier to access. We expect that this will...
Charging procedure: technology appraisal and highly specialised technologies evaluations
Introduction In accordance with UK Statutory Instrument 2018 No.1322 , NICE must recover its costs for producing Technology Appraisals (TA) or Highly
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA
Changes to charging for Technology Appraisal and Highly Specialised Technologies consultation
Take part in our consultation: 5 proposals about the way the NICE charges for TAs and HSTs.
Evidence-based recommendations on etrasimod (Velsipity) for moderately to severely active ulcerative colitis in people aged 16 and over.
This International Women’s Day, we’re specifically focusing on the invaluable contributions of two of the women who help shape our guidance through their independent / voluntary committee roles. Hear from them, as they talk about their involvement with NICE and what #InspireInclusion means to them.
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....
NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
We want you to tell us what matters to you, your organisation or your community.
To help us understand the needs of our users we are offering the opportunity to be directly involved in the work we do. Fellows, registrars and...
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
Digital technologies for managing non-specific low back pain: early value assessment (HTE16)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over....
View recommendations for HTE16Show all sections
A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.
All our committees include experienced professionals with knowledge of a particular topic within health or social care . Professional members also...
Find out more about being on a committee at NICE.
A public consultation on our new approach to prioritising guidance is now open
Running for 4 weeks, the consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
Achieving and demonstrating compliance with NICE TA and HST guidance
The NHS and patients need evidence that commissioners are funding medicines and treatments approved through the NICE Technology Appraisal (TA) or...
Support for industry to engage with NICE during all stages of health technology development
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
PDAs help people decide on healthcare options. They provide evidence-based information on the options available, along with likely outcomes, benefits,
Evidence-based recommendations on endoscopic sleeve gastroplasty for obesity. This involves using an endoscopic device to fold the stomach in on itself and stitch it together to reduce its volume.
View recommendations for IPG783Show all sections
Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE
New one-a-day tablet for people with severe hair loss due to alopecia areata recommended by NICE
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Putting our guidance into practice benefits patients and carers, healthcare professionals and organisations. Teams within NICE have a role in...
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
The different types of health, public health and social care information provided by NICE.
NICE guidance that could generate cost savings.
Biosimilar technologies: NICE position statement - information for the public
Biosimilar medicines – NICE's approach A biological medicine is any medicinal product made by or derived from a biological (natural) source, for...